CREBBP and prostate carcinoma: In a recent study, YO8197, a selective inhibitor of CBP bromodomain was explored in terms of its antitumor activity against prostate cancer cell lines in vitro [34] of which further in silico studies by akinsiku et al., proved the mechanistic and selective targeting of Y08197 at the bromodomain site.